UnknownPhase 2

the Study of Effect of Chronomodulated Chemotherapy on the Dendritic Cells Subsets in the Treatment of Advanced Nasopharyngeal Cancer

China128 participantsStarted 2017-04-07

Plain-language summary

This study is to observe and compare the effect of docetaxel plus lobaplatin induction chemotherapy combined with lopoplatin chemoradiotherapy and TPF induction chemotherapy combined with cisplatin chemoradiotherapy on dendritic cells subsets in the treatment of locally advanced head and neck squamous cell carcinoma.

Who can participate

Age range18 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. initial treatment of advanced nasopharyngeal carcinoma Ⅲ-Ⅳ patients with pathologically confirmed (according to 2010 UICC staging, T3-4, N0-3), without evidence of distant metastasis (M0). Have measurable tumor lesions.
✓. KPS≥70 points.
✓. the age of 18-70 years old, male or female.
✓. no major organ dysfunction; normal bone marrow function (WBC ≥4.0 × 109 / L, platelets ≥100 × 109 / L, hemoglobin ≥90g / L), normal liver function (total bilirubin, alanine aminotransferase, aspartate aminotransferase ≤1.5 times the upper limit of normal), normal renal function (creatinine ≤ 1.5 times upper limit of normal).
✓. understand this study and signed informed consent

Exclusion criteria

✕. Three months in the use of Chinese herbal medicine or immune modulators
✕. distant metastasis.
✕. who had received prior chemotherapy.
✕. patients have physical or mental illness, and by researchers believe that patients can not be completely or fully understood in this study possible complications.
✕. pregnancy (via the urine or serum β-HCG test confirmed) or during lactation. serious complications, such as uncontrolled hypertension, heart failure, diabetes and so on.

What they're measuring

Dendritic cell subgroup changes of Participants

Timeframe: termination of treatment, 3 months after treatment

Trial details

NCT IDNCT03196869

SponsorGuiyang Medical University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2019-04-12

Contact for this trial

Feng Jin, Bachelor

0851-86512802 jinf8865@yeah.net

View on ClinicalTrials.gov More Locally Advanced Head and Neck Squamous Cell Carcinoma trials